Medicare to cover Novo’s weight-loss drug Wegovy for patients with heart disease

[cafead]

via The Centers for Medicare and Medicaid Services announced on Thursday that it will cover Novo Nordisk’s blockbuster weight-loss medication Wegovy (semaglutide) for the reduction of the risk of heart attack, stroke and other related cardiovascular issues in patients who have preexisting heart disease, according to multiple media reports.

article source